Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Background: Metastasis is the spread of cancer from one organ to a nonadjacent organ. It causes 90% of cancer deaths. No treatment specifically prevents or reduces metastasis. Researchers hope a new drug can help. It stops cancer cells from growing and spreading further and possibly shrink cancer lesions in distant organs. Objective: To find a safe dose of metarrestin and to see if this dose shrinks tumors. Eligibility: Adults age 18 and older with pancreatic cancer, breast cancer, or a solid tumor that has not been cured by standard therapies. Also, children age 12-17 with a solid tumor (other than a muscle tumor) with no standard therapy options. Design: Participants will be screened with: * blood tests * physical exam * documentation of disease confirmation or tumor biopsy * electrocardiogram to evaluate the heart * review of their medicines and their ability to do their normal activities Participants will take metarrestin by mouth until they cannot tolerate it or stop to benefit from it. They will keep a medicine diary. Participants will visit the Clinical Center. During the first month there are two brief hospital stays required with visits weekly or every other week thereafter. They will repeat some of the screening tests. They will fill out questionnaires. They will have tests of their cognitive function. They will have an electroencephalogram to record brain activity. They will have a computed tomography (CT) scan or magnetic resonance imaging (MRI). A CT is a series of X-rays of the body. An MRI uses magnets and radio waves to take pictures of the body. Adult participants may have tumor biopsies. Participants will have a follow-up visit 30 days after treatment ends. Then they will have follow-up phone calls or emails every 6 months for the rest of their life or until the study ends.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat (lub 12-18 lat dla dzieci) z potwierdzonym nowotworem litym
- •Nowotwór, który nie może być całkowicie usunięty chirurgicznie lub wrócił po wcześniejszym zabiegu
- •Nowotwór rozprzestrzeniający się na inne organy lub mierzalny według standardowych kryteriów
- •Nowotwór, który się rozwinął lub wrócił mimo wcześniejszego leczenia chemioterapią
- •Wyzdrowiał z powikłań związanych z poprzednim leczeniem do poziomu łagodnego lub bez objawów
- •Dobra ogólna kondycja fizyczna (wynik 70% lub wyżej w skalach Karnofskiego/Lanskiego)
- •Prawidłowe wyniki badań krwi, funkcji wątroby i nerek
- •Osoby w wieku rozrodczym muszą stosować antykoncepcję przez czas badania i 120 dni po jego zakończeniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 12 Years
- Maximum age
- 120 Years
- Last updated (source)
- July 24, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
University of Kansas
Fairway, United States
National Institutes of Health Clinical Center
Bethesda, United States
Trial contact
Murielle Hogu
Udo Rudloff, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.